


 Cite this: *RSC Adv.*, 2021, **11**, 25738

Structure-based design, synthesis, and biological evaluation of novel piperine–resveratrol hybrids as antiproliferative agents targeting SIRT-2†

 Ahmed H. Tantawy,^a Xiang-Gao Meng,^{*d} Adel A. Marzouk,^e Ali Fouad,^e Ahmed H. Abdelazeem,^{fg} Bahaa G. M. Youssif,^h Hong Jiang^{*b} and Man-Qun Wang^{*a}

A series of novel piperine–resveratrol hybrids **5a–h** was designed, synthesized, and structurally elucidated by IR, and ¹H, ¹³C, and ¹⁹F NMR. Antiproliferative activities of **5a–h** were evaluated by NCI against sixty cancer cell lines. Compound **5b**, possessing resveratrol pharmacophoric phenolic moieties, showed a complete cell death against leukemia HL-60 (TB) and Breast cancer MDA-MB-468 with growth inhibition percentage of –0.49 and –2.83, respectively. In addition, **5b** recorded significant activity against the other cancer cell lines with growth inhibition percentage between 80 to 95. New **5a–h** hybrids were evaluated for their inhibitory activities against Sirt-1 and Sirt-2 as molecular targets for their antiproliferative action. Results showed that compounds **5a–h** were more potent inhibitors of Sirt-2 than Sirt-1 at 5 μm and 50 μm. Compound **5b** showed the strongest inhibition of Sirt-2 (78 ± 3% and 26 ± 3% inhibition at 50 μM and 5 μM, respectively). Investigation of intermolecular interaction *via* Hirschfeld surface analysis indicates that these close contacts are mainly ascribed to the O–H...O hydrogen bonding. To get insights into the Sirt-2 inhibitory mechanism, a docking study was performed where **5b** was found to fit nicely inside both extended C-pocket and selectivity pocket and could compete with the substrate acyl-Lys. Another possible binding pattern showed that **5b** could act by partial occlusion of the NAD⁺ C-pocket. Collectively, these findings would contribute significantly to better understanding the Sirt-2 inhibitory mechanism in order to develop a new generation of refined and selective Sirt-2 inhibitors.

 Received 25th May 2021
 Accepted 23rd June 2021

DOI: 10.1039/d1ra04061h

rsc.li/rsc-advances

^aHubei Insect Resources Utilization and Sustainable Pest Management Key Laboratory, College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, People's Republic of China. E-mail: mqwang@mail.hzau.edu.cn; ahmed.tantawy@mail.hzau.edu.cn

^bDepartment of Chemistry, College of Science, Huazhong Agricultural University, Wuhan, 430070, China. E-mail: jianghong0066@126.com

^cDepartment of Chemistry, College of Science, Benha University, Benha 13518, Egypt

^dKey Laboratory of Pesticide and Chemical Biology, Ministry of Education, School of Chemistry, Central China Normal University, Wuhan 430079, China. E-mail: xianggao_meng@126.com

^eDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut 71524, Egypt

^fDepartment of Medicinal Chemistry, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt

^gDepartment of Pharmaceutical Sciences, College of Pharmacy, Riyadh Elm University, Riyadh 11681, Saudi Arabia

^hPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt

† Electronic supplementary information (ESI) available. CCDC 1984255, 1984254, 2009516, 1984253, 1984251 and 1934954. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/d1ra04061h

1. Introduction

Since cancer is one of the world's leading major health problems causing death,^{1–3} finding and discovering new successful anticancer drugs is one of the biggest challenges in drug research. Sirtuins have attracted attention over the last decade because they have participated in the regulation of many processes that affect cancer cells,^{4,5} such as cellular metabolism,^{6,7} chromatin structure control and genomic stability maintenance.^{8,9} Sirtuins are part of a family of seven human enzymes (SIRT1–7), which are NAD-related histone deacetylases (HDACs).^{10,11} With NAD, SIRTs catalyze acetyl group removal from *N*-acetyl lysine amino acid on histone substrates which generates deacetylated proteins, nicotinamides and *O*-acetyl-ADP-ribose molecules.^{12,13} Isozyme Sirt-2 has taken part in several cellular processes such as gene transcription, genome constancies and cell cycle regulation during mitosis.^{14,15} Sirt-2 is a key factor in the development of cancer and metastasis by increasing cancer cell motility.¹⁶ In addition, Sirt-2 inhibition showed an increase in tumor suppressor genes, including p53 and p21.¹⁷ Small molecules that can control sirtuin activities are therefore considered potential therapeutics for the treatment of






Fig. 1 The modification of piperine structure and the impact on the anticancer activity.

various human disorders, including cancer. Knockdown or inhibition of Sirt-2 may disrupt the metabolism of cancer cells and thus prevent the spread and growth of cancer cells.^{18–21}

Natural products are one of the chief consistent sources of lead drugs. Developments based on natural products including various anticancer drugs such as topotecan, docetaxel, vindesine, etoposide and vinorelbine have been published.^{22,23} Natural products produced from bacterial, fungal, marine, plant and animal sources and natural product-inspired compounds have wide benefits in clinical trials as anti-inflammatory drugs, anticancer drugs, or other pharmaceutical agents.²⁴ It is estimated that natural product-derived compounds constitute more than 50% of anticancer agents; about 74% of anticancer compounds are either natural or natural product-inspired compounds.²⁵

Piperine, Fig. 1, is a nitrogenous alkaloid found in black pepper powder fruit that is widely used as a food flavor in a number of countries and used in many conventional food preservation systems as well as in traditional medicines.²⁶ Piperine was proven to have anticancer activity with various mechanisms of action. The substitution of the piperidine moiety with bulkier and extended groups has been reported to significantly enhance the potency as noted in compound 2, where the tryptophanyl moiety has been added.²²

On the other hand, the polyphenolic compounds such as resveratrol and piceatannol showed high affinity to the human

sirtuins family with a great modulating potential. The well-known stilbenoid polyphenol, resveratrol, was reported as a Sirt-1 and Sirt-5 activator while a weak Sirt-2 and Sirt-3 inhibitor.^{27–31} However, its metabolite piceatannol was found to act as an inhibitor to Sirt-2 protein.³¹ From the study of the reported SAR and the interactions with some SIRT proteins, it was conceptualized that the phenolic moieties have a remarkable impact on their SIRT activities.^{27–31} Till now, there are no reported studies addressing the binding pattern and the key interactions of resveratrol with Sirt-2 subtype despite the high degree of structural similarity between the conserved catalytic domains of the human sirtuins family. In order to explore this possible pattern and optimize its activity against Sirt-2 in particular, resveratrol was docked into the active site of Sirt-2 (pdb code: 4RMG) co-crystallized with the SirReal2 ligand using the Ligand Fit protocol found in Discovery Studio software 2.5. It was obvious from the docking results that resveratrol occupied a part of the extended C-site at the interface between the Rossmann-fold domain and the zinc-binding domain without any clashing with either the acyl-Lys substrate channel or the nicotinamide moiety of the co-factor NAD⁺. It was involved in only one conventional H-bond with the Ile-118 residue and some hydrophobic interactions with Leu-134, Leu-138, Tyr-139, Phe-143, and Phe-190 amino acids. This interpretation suggests a considerable possibility for further structural optimization, Fig. 2(A and B). This point can




Fig. 2 Docking of resveratrol into SIRT-2 3D structure (pdb code: 4RMG). (A) The disposition of resveratrol (orange) inside SIRT-2 active site where the protein is represented as a solid surface colored according to atom charges; (B) the predicted binding pattern and interactions of resveratrol within the active site of SIRT-2; (C) the suggested sites of structural modifications and elongation of resveratrol; green mesh represents the Acyl-Lys substrate channel and the red mesh represents the C-pocket of nicotinamide moiety of NAD⁺ co-factor (cyan). The poses were rendered as stick model and the residues are shown as smaller grey sticks. All hydrogens were removed for the purposes of clarity.






Fig. 3 The design strategy of the novel piperine–resveratrol hybrids. In this design, the piperine backbone was tethered to 1,3-dihydroxyphenyl moiety of resveratrol or piceatannol using an azomethine group as a linker via a fragment-based drug design approach to obtain the final pharmacophore. Then, SAR studies was performed through replacing the phenolic moiety by with various electron-donating and electron-withdrawing substituents.

be clearly rationalized by the small size of the resveratrol structure. Inspired by these findings, we thought that the elongation or extension of the resveratrol structure to protrude into the hydrophobic acyl-lysine tunnel surrounded by the highly conserved phenylalanines 119, 131, 234, 235 and Val233 or to partially occlude the NAD^+ C-pocket would be a promising approach to target and competitively inhibit the Sirt-2 isoform, Fig. 2(C). Thus, our strategy to increase the size of resveratrol or even utilizing its pharmacophoric phenolic moieties was accomplished by hybridization with the piperine structure via a hydrazino-linker in one scaffold, Fig. 3.

Moreover, several reports showed that piperine enhanced the *in vivo* bioavailability and ADME properties of resveratrol.³² Hence, a commercial combination of piperine with resveratrol is currently available in the market and it is promoted to have many health benefits in terms of improving strength and endurance. Additionally, this combination is used as antioxidant, cancer protective and for weight loss. Recently, it was found that the combination of resveratrol with the polyphenolic compounds such as piperine and curcumin has a significant activity against estrogen receptor-positive MCF-7 breast cancer cells however, the authors proposed the action was accomplished through reducing glyoxalase-1 (GLO1) activity.^{32,33}

Considering the aforementioned findings, a new hybrid scaffold has been designed bearing the resveratrol pharmacophoric features bound to the piperine backbone using a fragment-based drug design approach in order to target the sirtuins proteins, in particular Sirt-2, as molecular mechanism for the anticancer action of newly synthesized series, Fig. 3. To extend our study and investigate the SAR, a series of piperine derivatives were synthesized by replacement of phenolic moiety with various electron donating and electron withdrawing substituents. The identity of the newly synthesized hybrids **5a–h** was proved using ^1H , ^{13}C and ^{19}F NMR. Furthermore, the single-crystal structures of **5a–f** were unambiguously elucidated by X-ray crystallography. The anticancer activities of **5a–h** were evaluated by NCI against sixty cancer cell lines of nine different tissues.

2. Results and discussion

2.1. Chemistry


Scheme 1 outline the synthetic procedures for key intermediates **2**, **3**, and target compounds **5a–h**. According to Scheme 1, piperic acid **2** was formed by hydrolyzing piperine (**1**) with alcoholic KOH,³⁴ followed by a reaction with oxalyl chloride in



the presence of DMF as a catalyst to yield piperic acid chloride **3**.³⁵ Carbonyl compounds were treated with hydrazine hydrate to yield the corresponding hydrazones **4a-h**, which were then reacted with piperic acid chloride to yield the corresponding compounds **5a-h**. The synthesized compounds were elucidated by ¹H, ¹³C and ¹⁹F NMR.

The IR spectrum of **5b** revealed a broad band at 3432–3300 cm⁻¹ related to (OH) and strong stretching band at 1651 cm⁻¹ related to (C=O), which is consistent with the proposed structure. In the ¹H NMR of compound **5b**, two common singlet signals one at 13.10–13.18 ppm related to

pyridazinone ring (NHCO) and the other at 3.73–3.86 ppm associated with the benzylic protons. The ¹³C NMR spectra of **Va-f** showed the characteristic benzylic carbon at 35.1 ppm and the (C=O) at 168 ppm. The olefinic and aromatic carbons appeared at their expected chemical shifts.^{36–38} Interestingly, the prepared compounds are soluble in common organic solvents, such as CHCl₃, tetrahydrofuran, and Et₂O, and partially soluble in methanol and ethanol. Compounds **5a-f** easily yielded X-ray quality crystals from slow evaporation of a mixture solution of methanol and CH₂Cl₂ with the appropriate amount of **5a-f** at room temperature.



Scheme 1 Synthetic route for the synthesis of novel piperine-resveratrol hybrids **5a-h** Reagents and conditions: (a) KOH, 95% methanol, reflux, 48 h, 93%; (b) (COCl)₂, DCM, room temperature, 16 h; (c) NH₂NH₂, THF, reflux, 24 h (d) DCM, 0 °C, 64–82%.



2.2. Biology

2.2.1. Evaluation of *in vitro* antiproliferative activity for compounds 5a–h. The antiproliferative activity of the target compounds **5a–h** was screened against a panel of 60 cancer cell lines according to NCI-guidelines at concentration of 10 μM . The results for each compound (Table 1) were recorded as the percent of growth inhibition of treated cells compared to untreated control cells. Compound **5b** ($\text{R}_1 = \text{H}$, $\text{R}_2 = 2,4\text{-dihydroxyphenyl}$) was the most active among the tested compounds which directly reflects the influences of phenolic moieties on the antiproliferative activity of the title scaffold. **5b** possessing a complete cell death against leukemia HL-60 (TB) and Breast cancer MDA-MB-468 with growth inhibition percentage of -0.49 and -2.83 , respectively. In addition, **5b** recorded significant activity against leukemia cancer cell lines K-562 and MOLT-4, Non-small cell lung cancer cell lines NCI-H322M and NCI-H460, Colon cancer cell lines COLO 205, HCT-15 and HCT-116, CNS cancer cell lines SF-295 and SF-539, Melanoma cancer cell lines LOX IMVI and UACC-62, Ovarian cancer cell lines NCI/ADR-RES, OVCAR-3, and OVCAR-4, Renal cancer cell lines CAKI-1, ACHN, and UO-31, and Breast cancer MCF7 cell line with growth inhibition percentage between 80 to 95. On the other hand, compound **5a** ($\text{R}_1 = \text{H}$, $\text{R}_2 = 4\text{-hydroxyphenyl}$) showed moderate activity against the cancer cell lines studied with growth inhibition percentage between 17 to 73, Table 1. Compounds **5e** ($\text{R}_1 = \text{H}$, $\text{R}_2 = 2\text{-hydroxy-4-diethylaminophenyl}$) and **5h** ($\text{R}_1 = \text{CH}_3$, $\text{R}_2 = 4\text{-bromophenyl}$) showed good activities against most of cancer cell lines with growth inhibition percentage between 40 to 97, Table 1. Compounds **5c**, **5f** and **5g** bearing 3-methoxy-4-hydroxyphenyl, (bis(4-fluorophenyl)methylene) and 3,5-di-*tert*-butyl-2-hydroxyphenyl, respectively were found to be least effective against the studied cancer cell lines.

2.2.2. Sirtuins inhibitory activity of 5a–h hybrids. Sirtuin-TK assay was performed to estimate the Sirtuins inhibitory potential of **5a–h** (Tables 2 and 3). The results of this test strongly complemented the findings of cancer cell-based assessments. Generally, the piperine-resveratrol **5a–h** hybrids were found to be stronger inhibitors of Sirt2 than Sirt1 at 5 μM and 50 μM . Of the 8 compounds evaluated, 3 analogs (**5b**, **5e** and **5h**) were more likely to inhibit Sirt2 (>70% inhibition) than Sirt1 (<50% inhibition) at 50 μM . The other compounds were poor inhibitors of both enzymes. Of these compounds studied, **5b** ($\text{R}_1 = \text{H}$, $\text{R}_2 = 2,4\text{-dihydroxyphenyl}$) showed a potent inhibition of SIRT2 ($78 \pm 3\%$ and $26 \pm 3\%$ inhibition at 50 μM and 5 μM , respectively). Compared with compound **5b**, which has 2,4-dihydroxyphenyl moiety, compound **5a**, containing 4-hydroxyphenyl moiety, showed lower potency to inhibit SIRT2 ($72 \pm 3\%$ and $19 \pm 3\%$ inhibition at 50 μM and 5 μM , respectively). Replacement of the 4-hydroxy group in compound **5b** with 4-diethylamino in compound **5e** resulted in a slight reduction of the inhibitory SIRT2 values ($74 \pm 2\%$ and $24 \pm 3\%$ inhibition at 50 μM and 5 μM , respectively). A further analysis of the compound pairs [**5b** vs. **5e**] showed that **5e** (containing 4-hydroxy-3-methoxyphenyl) would likely have less potent SIRT2 inhibition ($58 \pm 3\%$ and $17 \pm 3\%$ inhibition at 50 μM and 5 μM ,

respectively) than compound **5b** (Table 3). Notably, **5h**, containing 4-bromophenyl moiety, showed promising potency with $75 \pm 3\%$ and $22 \pm 5\%$ SIRT2 inhibition at 50 μM and 5 μM , respectively.

We then evaluated the **5b**, **5e** and **5h** IC_{50} values against SIRT2, all of which inhibited SIRT2 by more than 75% at 50 μM compared to the SIRT2 selective inhibitor AGK2 as a reference. The results are listed in Table 4. Compound **5b** was the most potent one among the tested derivatives, with IC_{50} value of $21 \pm 3 \mu\text{M}$ in comparison to the reference AGK2 ($\text{IC}_{50} = 13.9 \pm 1 \mu\text{M}$).³⁹

2.2.3. Cell cycle analysis and apoptosis assay

2.2.3.1. Cell cycle analysis. Cell cycle analysis was conducted for the most active compound **5b** against human pancreatic cancer cell line MCF-7. The percentage of MCF-7 cells in the G0/G1 phase of the control cell cycle was 53.64%, with a significant decrease to 35.08% following treatment with compound **5b**, while the percentage of cells in the S phase was marginally reduced with compound **5b** (35.56%) compared to the control (36.41%) (Fig. 4). The percentage of MCF-7 human pancreatic cancer cell line in the G2/M phase increased to 34.36% following treatment with compound **5b**. In addition, it is clear that the percentage of apoptotic cells in the pre-G1 process increased from 1.79% for control of untreated MCF-7 human pancreatic cancer cells to 17.34% and 22.17% for controlled **5b** and doxorubicin cells, respectively (Fig. 4, Table 5). According to the above results, compound **5b** exhibited mainly cell cycle arrest during the Pre-G1 and G2/M phases. In addition, it is clear that the compound studied is not cytotoxic but anti-proliferative, triggering programmed cell death and cell cycle arrest.

2.3. Description of crystals 5a–f and Hirschfeld surface analysis

The Hirschfeld surfaces and fingerprint plots can be utilized to identify a type and region of intermolecular interactions, which are capable of being generated using Crystal-Explorer software.⁴⁰ Molecular Hirschfeld surface in a crystal structure is constructed based on the electron distribution. Its normalized contact distance (d_{norm}) based on both d_e , d_i and van der Waals radii of the atom is listed in the following equation. Then, intermolecular contacts in the crystal can be analyzed by a combination of d_e and d_i in the form of a 2D fingerprint plot as listed in the below equation.⁴¹ Complementary regions are visible in the fingerprint plots where one molecule acts as a donor ($d_e > d_i$) and the other as an acceptor ($d_e < d_i$). The fingerprint plots can be divided into highlighting particular close interactions between the two atoms.⁴² This decomposition enables the separation of contributions from different interaction types in the full fingerprint.

$$d_{\text{norm}} = (d_i - r_i^{\text{vdw}})/r_i^{\text{vdw}} + (d_e - r_e^{\text{vdw}})/r_e^{\text{vdw}}$$

Crystals of **5b** were determined at room temperature. X-ray experiments indicate that there are each one complete **5b** and one methanol solvent molecule in its asymmetric unit. The



Table 1 One dose assay of nine different cancer cell types of compounds 5a–h^a

Subpanel cancer cell lines	Growth% inhibition							
	5a	5b	5c	5d	5e	5f	5g	5h
Leukemia								
CCRF-CEM	32.40	81.02	12.13	20.48	78.30	—	—	44.26
HL-60(TB)	44.10	−0.49	—	—	97.35	—	—	15.88
K-562	58.83	88.37	10.48	56.11	82.42	—	—	40.06
MOLT-4	23.50	86.66	—	—	81.71	—	—	25.29
RPMI-8226	16.87	52.34	15.33	—	46.39	—	—	19.41
SR	64.02	78.74	—	62.05	82.38	36.26	—	93.31
Non-small cell lung cancer								
A549/ATCC	—	63.94	—	—	46.69	—	—	12.49
EKVX	—	79.77	—	—	47.83	—	—	24.99
HOP-62	—	72.86	—	—	71.47	—	—	33.23
HOP-92	—	46.60	—	—	51.62	13.77	—	11.51
NCI-H226	—	62.41	18.28	—	50.53	—	10.06	24.10
NCI-H23	—	70.00	—	—	50.33	—	—	—
NCI-H322M	18.48	82.25	14.74	—	66.83	—	—	36.51
NCI-H460	—	86.03	—	—	80.25	—	—	60.40
NCI-H522	22.76	78.87	21.98	11.67	87.48	—	—	19.91
Colon cancer								
COLO 205	—	86.03	—	—	60.08	—	—	—
HCC-2998	—	61.09	—	—	45.98	—	—	10.78
HCT-116	—	91.33	—	—	92.14	—	—	12.34
HCT-15	39.67	83.03	—	24.23	78.73	—	—	36.30
HT29	—	51.91	—	—	32.24	—	—	—
KM12	33.35	76.61	—	14.25	69.83	—	—	24.89
SW-620	19.77	73.5	—	—	67.68	—	—	25.44
CNS cancer								
SF-268	17.15	75.57	—	—	66.32	—	—	32.46
SF-295	—	86.23	—	—	58.30	—	—	—
SF-539	17.56	85.66	15.33	—	77.28	—	—	12.47
SNB-19	—	50.87	—	—	38.99	—	—	14.48
SNB-75	26.97	35.98	—	25.68	41.19	16.64	32.95	68.09
U251	—	68.74	—	—	56.75	—	—	16.04
Melanoma								
LOX IMVI	38.53	90.31	—	11.11	81.77	—	12.05	38.29
MALME-3M	—	59.69	—	—	43.47	—	—	28.67
M14	17.10	69.73	—	22.24	63.64	—	—	26.74
MDA-MB-435	73.02	67.38	—	70.14	51.12	—	—	13.60
SK-MEL-2	—	47.24	—	—	34.33	—	—	11.01
SK-MEL-28	—	57.87	—	—	47.95	—	—	14.25
UACC-257	—	71.52	—	—	75.82	—	—	12.00
UACC-62	28.50	85.74	11.32	16.06	70.87	12.19	—	28.51
Ovarian cancer								
IGROV1	24.72	71.10	—	10.14	61.80	12.09	14.13	29.67
OVCAR-3	—	90.27	—	—	95.06	—	—	24.42
OVCAR-4	12.67	90.76	—	—	84.74	—	—	65.24
OVCAR-5	—	57.55	—	—	39.11	—	—	10.69
OVCAR-8	—	77.21	—	—	67.09	—	—	24.67
NCI/ADR-RES	—	94.85	—	—	82.45	—	—	33.86
SK-OV-3	—	73.00	—	—	60.49	—	—	—
Renal cancer								
786-0	—	70.98	—	—	52.78	—	—	14.63
ACHN	—	85.61	—	—	74.37	—	—	24.09
CAKI-1	25.08	90.35	—	24.55	70.70	12.79	—	28.09
RXF 393	—	42.15	—	—	27.41	—	—	—
SN12C	—	67.24	—	—	45.91	—	—	12.40



Table 1 (Contd.)

Subpanel cancer cell lines	Growth% inhibition							
	5a	5b	5c	5d	5e	5f	5g	5h
TK-10	—	69.04	—	—	62.17	—	—	—
UO-31	39.21	88.57	14.03	23.71	75.03	18.30	27.88	44.91
Prostate cancer								
PC-3	19.78	62.05	—	15.03	59.10	—	—	30.92
DU-145	—	50.01	—	—	46.82	—	—	43.99
Breast cancer								
MCF7	28.77	85.87	20.13	43.56	80.48	—	—	38.66
MDA-MB-231/ATCC	17.21	65.61	—	—	56.75	—	—	21.03
HS 578 T	—	29.82	—	—	31.90	—	—	86.45
BT-549	21.48	72.73	13.62	—	48.23	—	—	—
T-47D	18.59	76.14	19.80	—	73.68	—	—	65.01
MDA-MB-468	—	-2.83	—	—	86.64	—	—	29.28

^a (—): complete cell death, (—): not calculated.

Table 2 Inhibitory activities of 5a–h against human SIRT1

Compound	% inhibition of SIRT1	
	5 μm	50 μm
5a	13 ± 3	42 ± 3
5b	18 ± 3	45 ± 3
5c	12 ± 1	38 ± 3
5d	11 ± 2	48 ± 3
5e	20 ± 5	44 ± 2
5f	14 ± 4	39 ± 3
5g	9 ± 2	35 ± 1
5h	16 ± 5	44 ± 3

Table 3 Inhibitory activities of 5a–h against human SIRT2

Compound	% inhibition of SIRT2	
	5 μm	50 μm
5a	19 ± 3	72 ± 3
5b	26 ± 3	78 ± 3
5c	17 ± 3	58 ± 3
5d	18 ± 2	70 ± 3
5e	24 ± 3	74 ± 2
5f	20 ± 4	69 ± 3
5g	19 ± 2	55 ± 1
5h	22 ± 5	75 ± 3

whole molecule shows a nearly flat configuration due to these several double bonds. The Hirschfeld surfaces of compound **5b** have been mapped over d_{norm} (Fig. 5a) and shape index (Fig. 5b). The intermolecular interactions mainly originated from hydroxyl oxygen and acyl hydrazone nitrogen atoms can be seen in the Hirschfeld surface as the bright red areas in Fig. 5a, and

the light red spots are corresponding to C–H...O and C–H... π interactions. The O...H/H...O intermolecular interactions (30.4%) appear as distinct spikes in the 2D fingerprint plot (Fig. 5d). In the fingerprint plots, there are two sharp spikes in the lower left of the plots due to the O/N–H...O hydrogen bonds (Fig. 5c). The proportion of O...H/H...O interactions comprises 30.4% of the total Hirschfeld surfaces. The points in the (d_i , d_e) regions around (1.168, 1.107) from the fingerprint plots belong to C–H... π interactions (17.2%) (Fig. 5e) which is mainly existing between the benzene ring and the methanol solvent at (2 – x , 1 – y , z). π ... π interactions are not represented because there are no typical ‘wings’ at the top left and bottom right of the two-dimensional fingerprint plot (Fig. 5f), occupying *ca.* 8.3% of the total Hirschfeld surface. For the crystal packing, the molecules of **5b** are linked by these O/N–H...O hydrogen bonds into a two-dimensional layer structure parallel to the (001) plane. These (001) layer structures are further linked into a three-dimensional network.

In the crystal structure of **5a** (Fig. S9[†]), there is one complete molecule and one methanol molecule in its asymmetric unit in which the component ions are linked into a one-dimensional hydrogen-bonded chain running along the [010] axis. A Hirschfeld surface analysis indicates that the H...O (25.6%), H...C (22.1%), C...C (5.9%) and H...H (38.7%) contacts in **5a** are comparable to those in crystal structure of **5b**.

Table 4 IC₅₀ values for the inhibitory activity of compounds **5b**, **5e** and **5h** against SIRT2 enzyme

Compound	IC ₅₀ (μm)
5b	21 ± 3
5e	23 ± 2
5h	26 ± 3
AGK2 (ref. 39)	13.9 ± 1






Fig. 4 Cell cycle analysis of **5b** in human pancreatic cancer cell line MCF-7.

In the crystal structure of **5c**, there is one complete molecule in its asymmetric unit in which the component ions are linked into a two-dimensional hydrogen-bonded layer structure parallel to the plane (20–1). A Hirschfeld surface analysis indicates that the contacts of H \cdots O, H \cdots C, C \cdots C and H \cdots H in the crystal packing of **5c** are 22.8%, 28.8%, 1.4% and 35.3% respectively (Fig. S10 \dagger). In **5d**, there is one complete molecule and two water molecules in its asymmetric unit in which the component ions are linked into a two-dimensional hydrogen-

bonded network parallel to the (001) plane. A Hirschfeld surface analysis for the host molecule indicates that the H \cdots O, H \cdots C and C \cdots C contacts including their reciprocal contacts are 19.2%, 27.1% and 3.2% of the total surface, respectively (Fig. S11 \dagger).

In **5e**, there is each one host molecule and one methanol molecule in its asymmetric unit. Analysis indicates the component ions are firstly linked into a one-dimensional hydrogen-bonded chain running along the [010] axis. These neighboring [010] chains are linked into a three-dimensional network by a combination of C–H \cdots π and $\pi\cdots\pi$ interactions. A Hirschfeld surface analysis indicates that the H \cdots O (19.7%), H \cdots C (17.4%), C \cdots C (5.4%) and H \cdots H (51.5%) contacts are also comparable to those in crystal structures above mentioned (Fig. S12 \dagger). In the crystal of **5f** (Fig. S13 \dagger), a dimer is formed by a pair of complementary N–H \cdots O hydrogen bonds. A Hirschfeld surface analysis indicates that the H \cdots O (including the reciprocal contacts) contacts comprise 13.9% of the total surface.

Table 5 Apoptosis induction analysis of compound **5b**

Sample code	Cell line	Apoptosis			% necrosis
		% total	% early	% late	
5b	MCF-7	6.16	2.74	2.29	1.13
Control	MCF-7	1.72	0.88	0.23	0.61






Fig. 5 Hirshfeld surfaces in **5b** mapped with (a) d_{norm} ; (b) shape index, (c) full fingerprint plot; (d) H...O contacts (O-H...O and N-H...O); (e) H...C contacts (C-H... π) and (f) C...C contacts (π ... π).

The H...C (C-H... π , 18.9%) and C...C (π ... π , 5.3%) are both comparable to those in **5b**.

From the Hirshfeld analysis, we can obviously see that the O/N-H...O hydrogen bonds are the main driving forces in the crystal packing. The C-H... π interactions also play an important role in the crystal aggregates. However, the π ... π interactions comprise the least of the total Hirshfeld surface in these five structures. We can also find that the lateral hydroxyl oxygen and acyl hydrazone nitrogen atoms are in favor of hydrogen-bonding to some other acceptors. To sum up above mentioned discussion, one can find that the O/N-H...O hydrogen bonds are preferred in the crystallization state. Although a crystallization state cannot be completely a representation of a solution state, it can still give us some hints when these molecules are used as antiproliferative inhibitors they may firstly interact with the target position of a protein through hydrogen bonds (*vide infra*).

2.4. Molecular docking study

In an attempt to rationalize the obtained *in vitro* Sirt-2 assay results, a molecular docking study of the most potent compound **5b** into the active site of human Sirt-2 was performed to elucidate the possible underlying inhibitory mechanisms and to predict the binding mode and the interactions that can be formed. The 3D crystal structure of Sirt-2 (PDB code: 4RMG) in complex with SirReal2 ligand and Co-factor NAD⁺ was used after preparation. The docking simulation was carried out using Ligand Fit embedded in Discovery Studio software 2.5 (San Diego, USA) according to the reported method.^{43–46} Analysis of

the top-ranked pose of compound **5b** demonstrated several plausible molecular interactions and various binding patterns, Fig. 6A. It was reported that the active site of Sirt-2 could be divided into several sites. The C-pocket accommodates the nicotinamide moiety of the co-factor NAD⁺ while the acetyl-Lys substrate binding channel is formed by several hydrophobic phenylalanine's. In addition, there is a pocket close to the C-pocket and link the inducible selectivity pocket in Sirt-2 with the acyl-Lys tunnel called extended C-site, Fig. 6(B).^{47,48}

From a precise inspection of the results, it was conceptualized that there are two possible different hypotheses or binding patterns can be used to rationalize the inhibitory activity of our compound **5b** against SIRT-2: (I) our newly synthesized hybrid molecule **5b** adopts a very similar binding mode consistent with that of the co-crystallized ligand, SirReal2 where it binds to the extended C-site as well as to the reported selectivity pocket that formed by two loops of the hinge region connecting the Rossmann-fold and zinc-binding domains. The binding pattern analysis revealed that 1,3-dihydroxyphenyl moiety of **5b** can be accommodated into the lipophilic selectivity pocket in a manner similar to the dimethyl mercapto-pyrimidine residue of SirReal2 maintaining the same π - π stacking with Phe190. In addition, two hydrogen bonds were formed between the two hydroxyl groups of **5b** and Ala135 and Ile169 residues. The rest of the **5b** kinked conformation occupies the Extended C-site adjacent to the C-pocket and it is oriented towards the acetyl-lysine substrate tunnel. The benzodioxolyl moiety of **5b** protrudes into the substrate channel forming hydrophobic interactions with Phe119, Phe131, Ile232, Val233 and Phe234 amino acids. This bulky benzodioxolyl moiety equivalent to the






Fig. 6 Docking of compound **5b** into SIRT-2 3D structure (pdb code: 4RMG). (A) Overlay of the top docked poses **5b** (green and violet) and SirReal-2 (yellow) as a co-crystallized ligand into the Sirt-2 binding site where the Sirt-2 protein is represented as secondary structure displayed in a flat ribbon style (cartoon) colored in black-white; (B) labelling of the different binding pockets of Sirt-2 protein. The NAD⁺ co-factor (cyan) is displayed in stick.

naphthyl moiety of SirReal2, is thought to force the acetyl-lysine out of its physiological position in a competitive inhibitory manner. Interestingly, the **5b** structure is longer than sirReal2 one which in turn will likely compete with the acyl-Lys substrate in a stronger way. In this hypothesis, **5b** does not interfere with the C-pocket where nicotinamide moiety of NAD⁺ binds, Fig. 7A–C.

(II) Another considerable binding mode was observed where **5b** binds in an inverted fashion to what was adopted in the former hypothesis. It was found that the benzodioxolyl moiety induces the formation of the selectivity pocket instead of the dihydroxyphenyl in a similar manner to that of sirReal2 forming the reported π - π stacking with Phe190. However, the dihydroxyphenyl moiety was oriented downwards toward the C-




Fig. 7 The first hypothesis of binding pattern of **5b** inside Sirt-2 active site; (A) overlay of the top docked poses **5b** (green and violet) and SirReal-2 (yellow) as a co-crystallized ligand into the secondary structure of Sirt-2 active pocket; (B) the interactions and binding mode of **5b** (green) inside the Sirt-2 active sites (extended C-pocket and selectivity pocket); (C) superimposition of **5b** (green) and SirReal2 (yellow). The poses were rendered as stick model. π - π interactions were represented as orange solid line. Hydrogen bonds were represented as dashed green lines.






Fig. 8 The second hypothesis of binding pattern of **5b** inside Sirt-2 active site; (A) overlay of the top docked poses **5b** (green and violet) and SirReal-2 (yellow) as a co-crystallized ligand into the secondary structure of Sirt-2 active pocket; (B) the interactions and binding mode of **5b** (violet) inside the Sirt-2 active sites (Extended C-pocket and selectivity pocket); (C) the window shows magnification of the possible clash between **5b** (violet) and the NAD⁺ co-factor (cyan). The rest of NAD⁺ was removed for clarity. The poses were rendered as stick model. π - π interactions were represented as orange solid line. Hydrogen bonds were represented as dashed green lines.

pocket where the nicotinamide moiety of NAD⁺ binds and initializes the deacetylation reaction. This conformation is stabilized by forming a hydrogen bond with His187. Another hydrophobic interaction between the unsaturated alkenyl chain of **5b** and the gate keeper, Phe96 residue, which helps nicotinamide to release and prevents the backward reaction was observed. It was also noted that **5b** was highly distorted from the extended C-site or the substrate tunnel and did not have strong hydrophobic contact with Phe119, Phe131, Ile232, Val233 and Phe234 amino acids residue, Fig. 8A–C. This hypothesis suggested that **5b** might partially occupy the C-pocket and occlude or compete with nicotinamide moiety of NAD⁺ in contrary to the sirReal2 mechanism which is partially non-competitive towards NAD⁺. We think that the former hypothesis is a much more reasonable explanation for the inhibitory activity of **5b** against Sirt-2 where it shows the highest ranked binding pattern with the lowest energy score. Moreover, targeting both selectivity pocket and the substrate channel by linking two distinct moieties in one scaffold is much more acceptable and significant mechanism for inhibition of Sirt-2. Indeed, we will need further kinetic competition studies to distinguish and prove one of these two inhibitory mechanisms. However, these results support the hypothesis that targeting either the acyl-Lys substrate binding site or NAD⁺ co-factor C-pocket represents a useful approach to develop novel and potent SIRT2 competitive inhibitors.

3. Conclusion

In this study, a series of piperine-resveratrol hybrids **5a–h** was designed and synthesized as inhibitors of Sirt-2. A panel with sixty

cancer cell lines of nine different tissues in compliance with the NCI protocol has been utilized for the evaluation of **5a–h** hybrids. Compounds **5b**, **5e** and **5h** showed significant antiproliferative activity. **5a–h** were found to be more potent inhibitors of Sirt-2 than Sirt-1. Results of cell cycle investigation showed that 3.64% of pre-G1 apoptosis was induced by compound **5b** on MCF-7 with a high percentage of cell accumulation in G2-M phase. In these complexes with the hydroxyl groups, the component ions are mainly linked into a 3D framework by a combination of O–H \cdots O hydrogen bonds, C–H \cdots O, C–H \cdots π and π \cdots π interactions. Hirschfeld surface analysis indicates that O–H \cdots O hydrogen bonds consist of *ca.* 20% of the total surface, which indicate that in the biological system the O–H \cdots O interaction may be mainly attributed to their biological characteristics. A docking study of the most active compound **5b** was carried out to get insights into the Sirt-2 inhibitory mechanism and justify the *in vitro* results. The results revealed two possible binding patterns of **5b** that could be used to rationalize its Sirt-2 inhibitory activity by either competition with acyl-Lys substrate or partially blocking co-factor NAD⁺ C-pocket. These findings highlight the importance of Sirt-2 as a promising anticancer target and open a new avenue to develop novel superior and selective Sirt-2 inhibitors.

4. Experimental

4.1. Chemistry

General details and crystallographic data (Table S1): see ESI[†] and Appendix A.

4.1.1. Synthesis of (2E,4E)-5-(benzo[d][1,3]dioxol-5-yl) penta-2,4-dienoyl chloride (3). Compounds **2** and **3** were



prepared according to our previous research work³⁵ and the experimental details are recorded in Appendix A.

4.1.2. Synthesis of hydrazone derivatives (4a–h).^{49–51} To a solution of carbonyl compounds (2.5 mmol), hydrazine monohydrate (158 μL , 3.25 mmol) in THF solution was added and refluxed for 24 h. Then the hydrazone solution was dried by 200 mg anhydrous Na_2SO_4 for 0.5 h and then 5 \AA molecular sieves powder (250 mg) for 5–6 h. The obtained hydrazones **4a–h** were utilized directly to the next step.

4.1.3. General procedure for synthesis of piperine-based hydrazone derivatives (5a–h). Compound **3** (191 mg, 1.1 mmol) was dissolved in CH_2Cl_2 (5 mL) and was added dropwise into a mixture of the hydrazones (**4a–h**, 100 mg, 1 mmol) in CH_2Cl_2 (5 mL) in ice bath. After addition of compound **3**, the reaction mixture was stirred for 7 h at room temperature, and then the solvent was removed under reduced pressure. The crud product was treated with Na_2CO_3 solution, then extracted three times by ethyl acetate. The organic layer was dried over Na_2SO_4 and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (CH_2Cl_2 : MeOH = 20 : 1) to give the corresponding compounds **5a–h** (69.1–89.2% yields). Crystals were grown after slow evaporation of a mixture solution of methanol and CH_2Cl_2 (2 : 3) with the appropriate amount of **5a–f**, then left open to the atmosphere at room temperature, producing yellow sheets and cubic crystals after 45 days.

4.1.3.1. (2E,4E)-5-(Benzo[d][1,3]dioxol-5-yl)-N'-((E,Z)-4-hydroxybenzylidene)penta-2,4-dienehydrazide (5a). Pale yellow solid, m.p. 12–127 $^\circ\text{C}$, yield: 83%; IR: 3463, 3104 3050, 2890, 1660, 1600, 1500, 1448, 1400, 1384, 1260. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 11.40 (s, 0.49H, NH), 11.20 (s, 0.46H, NH), 9.98 (d, 0.51H, OH), 9.91 (d, 0.46H, OH), 8.12 (s, 0.51H, 1H, $\text{CH}=\text{N}$), 7.93 (s, 0.46H, 1H, $\text{CH}=\text{N}$), 7.54 (d, J = 8.6 Hz, 2H), 7.41–7.26 (m, 2H), 7.20–7.07 (m, 1H), 7.02 (dd, J = 15.7, 6.3 Hz, 1H), 6.99–6.95 (m, 1H), 6.93 (dd, J = 8.0, 4.3 Hz, 1H), 6.83 (d, J = 8.6 Hz, 2H), 6.15 (d, J = 14.9 Hz, 1H), 6.06 (d, J = 2.8 Hz, 2H, $-\text{OCH}_2\text{O}-$). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 166.47, 161.91, 159.81, 159.57, 148.45, 148.37, 147.12, 131.31, 131.25, 129.34, 129.21, 128.93, 128.79, 125.82, 123.33, 116.23, 116.04, 109.02, 106.23, 106.07, 101.79. $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_5$, crystal dimensions $0.12 \times 0.1 \times 0.1 \text{ mm}^3$, M_r = 368.38, monoclinic, space group $P2_1/n$ (14) cell: a = 10.9249(5), b = 6.5740(3), c = 25.7341(11) \AA , α = 90 $^\circ$, β = 94.790(3) $^\circ$, γ = 90 $^\circ$, V = 1841.78(14) \AA^3 , Z = 4, density (calculated) = 1.329 g m^{-3} , μ = 0.799 mm^{-1} , $F(000)$ = 776.0, reflection collected/unique = 10 352/3035, refinement method = full-matrix least-squares on F^2 , Final R indices [$I > 2\sigma(I)$]: R_1 = 0.0925, wR_2 = 0.2368, R indices (all data): R_1 = 0.1011, wR_2 = 0.2530, goodness of fit on F^2 = 1.026. CCDC 1984251 (Fig. 9A).

4.1.3.2. (2E,4E)-5-(Benzo[d][1,3]dioxol-5-yl)-N'-((E)-2,4-dihydroxybenzylidene)penta-2,4-dienehydrazide (5b). Yellow solid, m.p. 153–156 $^\circ\text{C}$, yield: 80%; IR: 3432, 3300, 3030, 2902, 1650, 1602, 1515, 1439, 1367, 1252. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 11.64 (s, 1H, NH), 11.38 (s, 1H, OH), 9.95 (s, 1H, OH), 8.24 (d, J = 4.8 Hz, 1H, $\text{CH}=\text{N}$), 7.38–7.31 (m, 1H), 7.29 (d, J = 7.8 Hz, 2H), 7.07–6.96 (m, 3H), 6.93 (t, J = 8.2 Hz, 1H), 6.37–6.28 (m, 2H), 6.14 (d, J = 14.9 Hz, 1H), 6.06 (s, 2H, $-\text{OCH}_2\text{O}-$). ^{13}C NMR (151 MHz, $\text{DMSO}-d_6$) δ 166.4, 164.1, 161.9, 150.3, 148.5, 142.5,

141.5, 140.9, 140.1, 136.0, 131.2, 126.2, 125.9, 125.6, 123.9, 123.6, 121.9, 117.6, 114.9, 113.2, 111.1, 109.0, 106.4, 102.0. $\text{C}_{20}\text{H}_{20}\text{N}_2\text{O}_6$, crystal dimensions $0.12 \times 0.1 \times 0.1 \text{ mm}^3$, M_r = 384.38, monoclinic, space group $P2_1/c(14)$ cell: a = 6.6192(6), b = 19.7039(17), c = 14.2723(13) \AA , α = 90 $^\circ$, β = 99.079(5) $^\circ$, γ = 90 $^\circ$, V = 1841.78(14) \AA^3 , Z = 4, density (calculated) = 1.389 g m^{-3} , μ = 0.866 mm^{-1} , $F(000)$ = 808.0, reflection collected/unique = 10 609/2973, refinement method = full-matrix least-squares on F^2 , Final R indices [$I > 2\sigma(I)$]: R_1 = 0.0461, wR_2 = 0.1239, R indices (all data): R_1 = 0.0507, wR_2 = 0.1332, goodness of fit on F^2 = 1.074. CCDC 1984253 (Fig. 9B).




Fig. 9 The X-ray single crystal structures of **5a** (A) and **5b** (B).

4.1.3.3. (2E,4E)-5-(Benzo[d][1,3]dioxol-5-yl)-N'-((E,Z)-4-hydroxy-3-methoxybenzylidene)penta-2,4-dienehydrazide (5c). Pale yellow solid, m.p. 210–213 $^\circ\text{C}$, yield: 76.4%; IR: 3401, 3231, 3029, 2909, 2831, 1624, 1606, 1507, 1445, 1375, 1337, 1258. ^1H NMR (600 MHz, $\text{DMSO}-d_6$) δ 11.44 (s, 0.55H, NH), 11.25 (s, 0.43H, NH), 9.54 (s, 0.53H, OH), 9.50 (s, 0.39H, OH), 8.13 (s, 0.51H, 1H, $\text{CH}=\text{N}$), 7.93 (s, 0.40H, 1H, $\text{CH}=\text{N}$), 7.50–7.23 (m, 3H), 7.19–7.06 (m, 2H), 7.03 (dd, J = 10.3, 7.8 Hz, 1H), 6.99 (s, 1H), 6.93 (d, J = 13.2 Hz, 1H), 6.85 (s, 1H), 6.18 (d, J = 14.9 Hz, 1H), 6.06 (d, J = 1.7 Hz, 2H, $-\text{OCH}_2\text{O}-$), 3.85 (d, J = 18.9 Hz, 3H, OCH_3). ^{13}C NMR (150 MHz, $\text{DMSO}-d_6$) δ 166.46, 161.95, 149.39, 149.11, 148.48, 148.44, 148.37, 147.38, 143.74, 142.86, 141.50, 139.63, 139.35, 131.25, 126.26, 126.22, 125.68, 123.41, 123.01, 122.51, 121.41, 120.34, 116.06, 115.89, 110.25, 109.47, 108.94, 106.16, 101.79, 56.18. $\text{C}_{20}\text{H}_{18}\text{N}_2\text{O}_5$, crystal dimensions $0.12 \times 0.1 \times 0.1 \text{ mm}^3$, M_r = 366.36, monoclinic, space group $P2_1/c$ (14) cell: a = 18.1988(7), b = 4.8105(2), c = 22.1672(8) \AA , α = 90 $^\circ$, β = 112.874(3) $^\circ$, γ = 90 $^\circ$, V = 1788.03(13) \AA^3 , Z = 4, density (calculated) = 1.361 g m^{-3} , μ = 0.822 mm^{-1} , $F(000)$ = 768.0, reflection collected/unique = 14 927/3069, refinement method = full-matrix least-squares on F^2 , final R indices [$I > 2\sigma(I)$]: R_1 = 0.0490, wR_2 = 0.1431, R indices (all data): R_1 = 0.0687, wR_2 = 0.1575, goodness of fit on F^2 = 1.052. CCDC 2009516.

4.1.3.4. (2E,4E)-5-(Benzo[d][1,3]dioxol-5-yl)-N'-((E/Z)-4-(dimethylamino)-benzylidene)penta-2,4-dienehydrazide (5d). Pale yellow solid, m.p. 203–207 $^\circ\text{C}$, yield: 69.1%; IR: 3136, 3053, 2932,



2853, 1640, 1610, 1497, 1447, 1372, 1340, 1260. ^1H NMR (600 MHz, DMSO-*d*6) δ 11.31 (s, 0.54H, NH), 11.12 (s, 0.42H, NH), 8.08 (s, 0.56H, CH), 7.93 (s, 0.44H, CH), 7.52 (dd, $J = 8.9, 2.7$ Hz, 2H), 7.43–7.24 (m, 2H), 7.22–6.89 (m, 4H), 6.74 (dd, $J = 8.8, 4.2$ Hz, 2H), 6.15 (d, $J = 14.9$ Hz, 1H), 6.06 (d, $J = 2.4$ Hz, 2H, –OCH₂O–), 2.97 (s, 6H, N(CH₃)₂). ^{13}C NMR (150 MHz, DMSO-*d*6) δ 166.26, 151.92, 151.75, 148.44, 148.39, 148.33, 147.63, 141.22, 131.33, 131.29, 128.93, 128.79, 128.52, 128.38, 123.42, 122.91, 122.14, 112.39, 112.13, 109.02, 108.87, 106.21, 106.06, 101.78, 40.40. C₂₁H_{24.75}N₃O_{4.42}, crystal dimensions 0.12 × 0.04 × 0.03 mm³, $M_r = 389.87$, monoclinic, space group $P2_1/n$ (14) cell: $a = 13.6957(16)$, $b = 6.3687(7)$, $c = 24.058(3)$ Å, $\alpha = 90^\circ$, $\beta = 104.090(6)^\circ$, $\gamma = 90^\circ$, $V = 2035.3(4)$ Å³, $Z = 4$, density (calculated) = 1.272 g m⁻³, $\mu = 0.740$ mm⁻¹, $F(000) = 828.0$, reflection collected/unique = 9153/2692, refinement method = full-matrix least-squares on F^2 , final R indices [$I > 2\sigma(I)$]: $R_1 = 0.0706$, $wR_2 = 0.1880$, R indices (all data): $R_1 = 0.1081$, $wR_2 = 0.2150$, goodness of fit on $F^2 = 1.029$. CCDC 1984254.

4.1.3.5. (2*E*,4*E*)-5-(Benzo[*d*][1,3]dioxol-5-yl)-*N'*-((*E*)-4-(diethylamino)-2-hydroxy benzylidene)penta-2,4-dienehydrazide (5*e*). The spectroscopic analysis matched with those previously our work published³⁵ and included in appendix A.

4.1.3.6. (2*E*,4*E*)-5-(Benzo[*d*][1,3]dioxol-5-yl)-*N'*-(bis(4-fluorophenyl)methylene)penta-2,4-dienehydrazide (5*f*). Deep yellow solid, m.p. 190–193 °C, yield: 71.7%; IR: 3276, 3052, 2989, 2895, 1650, 1623, 1595, 1486, 1384, 1339, 1255. ^1H NMR (600 MHz, DMSO-*d*6) δ 10.24 (s, 0.59H, NH), 9.61 (s, 0.44H, NH), 7.52 (d, $J = 2.9$ Hz, 2H), 7.41 (s, 2H), 7.38 (d, $J = 8.4$ Hz, 2H), 7.31 (s, 1H), 7.24 (s, 3H), 6.92 (t, $J = 4.6$ Hz, 4H), 6.36 (d, $J = 14.7$ Hz, 1H), 6.05 (s, 2H, –OCH₂O–). ^{13}C NMR (151 MHz, DMSO-*d*6) δ 164.02, 162.39, 148.44, 143.81, 141.82, 139.57, 131.69, 131.17, 129.97, 126.24, 125.51, 123.41, 117.00, 115.92, 108.98, 106.16, 101.81. ^{19}F NMR (565 MHz, DMSO-*d*6) δ –106.46. C₂₅H₁₈F₂N₂O₃, crystal dimensions 0.20 × 0.12 × 0.10 mm³, $M_r = 432.41$, monoclinic, space group $P2_1/n$ (14) cell: $a = 5.329(3)$, $b = 10.708(5)$, $c = 15.496(7)$ Å, $\alpha = 83.878(9)^\circ$, $\beta = 87.608(9)^\circ$, $\gamma = 82.240(9)^\circ$, $V = 870.8(7)$ Å³, $Z = 4$, density (calculated) = 1.649 g m⁻³, $F(000) = 448$, reflection collected/unique = 6085/3045, refinement method = full-matrix least-squares on F^2 , final R indices [$I > 2\sigma(I)$]: $R_1 = 0.0623$, $wR_2 = 0.1690$, R indices (all data): $R_1 = 0.0965$, $wR_2 = 0.1941$, goodness of fit on $F^2 = 1.029$. CCDC 1984255.

4.1.3.7. (2*E*,4*E*)-5-(Benzo[*d*][1,3]dioxol-5-yl)-*N'*-((*E*)-3,5-di-*tert*-butyl-2-hydroxy-benzylidene)penta-2,4-dienehydrazide (5*g*). Deep yellow solid, m.p. 208–211 °C, yield: 72.3%; IR: 3449, 3360, 3050, 2957, 2820, 1663, 1615, 1594, 1445, 1385, 1362, 1254. ^1H NMR (600 MHz, DMSO-*d*6) δ 12.19 (s, 1H, NH), 11.94 (s, 1H, OH), 8.36 (s, 1H, CH=N), 7.40 (dd, $J = 15.0, 9.7$ Hz, 1H), 7.30 (s, 2H), 7.24 (d, $J = 2.3$ Hz, 1H), 7.03 (dd, $J = 12.9, 3.2$ Hz, 3H), 6.94 (s, 1H), 6.19 (d, $J = 14.9$ Hz, 1H), 6.06 (s, 2H, –OCH₂O–), 1.41 (s, 9H, 3CH₃), 1.26 (s, 9H, 3CH₃). ^{13}C NMR (151 MHz, DMSO-*d*6) δ 161.93, 155.08, 150.34, 148.51, 148.46, 142.49, 140.88, 140.08, 136.04, 131.15, 126.20, 125.94, 125.55, 123.60, 121.85, 117.55, 108.98, 106.20, 101.82, 35.11, 34.36, 31.77, 29.76.

4.1.3.8. (2*E*,4*E*)-5-(Benzo[*d*][1,3]dioxol-5-yl)-*N'*-((*E*)-1-(4-bromophenyl)ethylidene)penta-2,4-dienehydrazide (5*h*). Deep yellow solid, m.p. 188–192 °C, yield: 69.1%; IR: 3285, 3061, 2941, 2811, 2779, 1644, 1607, 1539, 1497, 1447, 1370, 1256. ^1H NMR

(600 MHz, DMSO-*d*6) δ 10.60 (s, 1H, OH), 7.77 (d, $J = 7.6$ Hz, 2H), 7.62 (d, $J = 8.5$ Hz, 2H), 7.38 (dd, $J = 27.5, 13.6$ Hz, 2H), 7.14 (d, $J = 14.1$ Hz, 1H), 7.01 (dd, $J = 29.7, 6.8$ Hz, 2H), 6.93 (d, $J = 8.0$ Hz, 1H), 6.48 (d, $J = 14.9$ Hz, 1H), 6.06 (s, 2H, –OCH₂O–), 2.28 (d, $J = 16.7$ Hz, 3H). ^{13}C NMR (151 MHz, DMSO-*d*6) δ 166.56, 148.46, 146.69, 143.03, 141.61, 139.65, 139.41, 131.24, 129.11, 128.73, 127.39, 126.26, 125.68, 123.44, 122.94, 120.27, 114.77, 108.95, 106.16, 101.79, 28.41.

4.2. Biology

4.2.1. **Screening of cytotoxic activity.** The methodology of the NCI anticancer screening has been described in detail elsewhere (<https://dtp.cancer.gov/>).⁵²

4.2.2. **Sirtuin inhibitory assay.** Sirt-1 and Sirt-2 inhibitory assay was performed to evaluate the inhibitory potency of 5*a*–**h** against Sirt-1 and Sirt-2.⁵³ See ESI.†

4.2.2.1. **Cell apoptosis assay.** Apoptosis was determined by flow cytometry based on the Annexin-V-fluoresce in isothiocyanate (FITC) and propidium iodide (PI) staining kit (BD Pharmingen, San Diego, USA).^{54,55} See ESI.†

Conflicts of interest

The authors declare no competing financial interest.

Acknowledgements

This work was supported by the National Key Research and Development Program of China (2017YFE0113900) and Huazhong Agriculture University, Talent Young Scientist Program (Grant No. 42000481-7).

References

- B. G. M. Youssif, M. H. Abdelrahman, A. H. Abdelazeem, M. A. abdelgawad, H. M. Ibrahim, O. I. A. Salem, M. F. A. Mohamed and L. Treambly, *Eur. J. Med. Chem.*, 2018, **146**, 260–273.
- A. H. Abdelazeem, M. T. El-Saadi, E. Gaber, B. G. M. Youssif and H. A. Omar, *Bioorg. Chem.*, 2017, **75**, 127–138.
- M. S. Abdelbaset, G. E. A. Abu-Rahma, M. H. Abdelrahman, M. Ramadan, B. G. M. Youssif, S. N. A. Bukhari and M. F. A. Mohamed, *Bioorg. Chem.*, 2018, **80**, 151–163.
- J. Hu and H. Jing, *Future Med. Chem.*, 2014, **6**, 945–966.
- M. Mottamal, S. Zheng and T. Huang, *Molecules*, 2015, **20**, 3898–3941.
- X. Ye, M. Li, T. Hou, T. Gao and W. G. Zhu, *Oncotarget*, 2017, **8**, 1845–1859.
- S. M. Jeong, *Mol. Cells*, 2015, **38**, 750–758.
- X. Wu, N. Cao and M. Fenech, *DNA Cell Biol.*, 2016, **35**, 542–575.
- V. L. Bosch-Presegu_e, *FEBS J.*, 2015, **282**, 1745–1767.
- S. A. Bedalov and S. Chowdhury, *Methods Enzymol.*, 2016, **574**, 183–211.
- P. Bheda, H. Jing and C. Wolberger, *Rev. Biochem.*, 2016, **85**, 405–429.



- 12 E. Therrien, G. Larouche, N. Nguyen, J. Rahil, A. M. Lemieux, Z. Li, J. J. W. T. P. Yan, A. J. Landry and S. Lefebvre, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 2514–2518.
- 13 N. Garmpis, C. Damaskos, A. Garmpi, D. Dimitroulis, E. Spartalis, G. A. Margonis, D. Schizas, I. Deskou, C. Doula and E. Magkouti, *Anticancer Res.*, 2017, **37**, 5355–5362.
- 14 Y. L. Wang, H. Chen, Y. Q. Zhan, R. H. Yin, C. Y. Li, C. H. Ge and M. Yu, *Cell Cycle*, 2016, **15**, 2202–2215.
- 15 T. Wang, Z. Xu, Y. Lu, J. Shi, W. Liu, C. Zhang, Z. Jiang and B. Qi, *Curr. Top. Med. Chem.*, 2019, **19**, 1051–1058.
- 16 Y. Li, M. Zhang, R. G. Dorfman, Y. Pan, D. Tang, L. Xu, Z. Zhao, Q. Zhou, L. Zhou and Y. Wang, *Neoplasia*, 2018, **20**, 745–756.
- 17 T. Eckschlager, J. Plch and M. Stiborova, *Int. J. Mol. Sci.*, 2017, **18**, 1–25.
- 18 Y. Huang, S. Zhao, Z. Tang, D. Zhou, Q. Li, Y. Zhou, L. Yin, Y. Wang, Y. Pan, T. Dorfman and R. G. Ling, *Transl. Oncol.*, 2017, **10**, 917–927.
- 19 S. Kaladhar and D. S. Kant, *Metabolism*, 2017, **4**, 162–185.
- 20 N. George and J. Ahmad, *Cancer Res.*, 2016, **76**, 2500–2506.
- 21 C. K. Singh, G. Chhabra, M. A. Ndiaye, L. M. Garcia-Peterson and N. J. Mack, *Antioxid. Redox Signaling*, 2018, **28**, 643–661.
- 22 P. Umadevi, K. Deepti and D. V. R. Venugopal, *Med. Chem. Res.*, 2013, **22**, 5466–5471.
- 23 Y. Deng, S. Sriwiriyan, A. Tedasen, P. Hiransai and P. Graidist, *J. Ethnopharmacol.*, 2016, **188**, 87–95.
- 24 L. Katz and R. H. Baltz, *J. Ind. Microbiol. Biotechnol.*, 2016, **43**, 155–176.
- 25 D. J. Newman, G. M. Cragg and K. M. Snader, *J. Nat. Prod.*, 2003, **66**, 1022–1037.
- 26 Y. Ali, M. S. Alam, H. Hamid, A. Husain, S. Bano, A. Dhulap, C. Kharbanda, S. Nazreen and S. Haider, *Eur. J. Med. Chem.*, 2015, **92**, 490–500.
- 27 R. C. Conaway, C. S. Brower, J. W. Conaway and H. D. Ulrich, *Annu. Rev. Cell Dev. Biol.*, 1999, **9**, 107–112.
- 28 J. C. Milne, P. D. Lambert, S. Schenk, D. P. Carney, J. J. Smith, D. J. Gagne, L. Jin, O. Boss, R. B. Perni, C. B. Vu, J. E. Bemis, R. Xie, J. S. Disch, P. Y. Ng, J. J. Nunes, A. V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D. A. Sinclair, J. M. Olefsky, M. R. Jirousek, P. J. Elliott and C. H. Westphal, *Nature*, 2007, **450**, 712–716.
- 29 J. Trapp, A. Jochum, R. Meier, L. Saunders, B. Marshall, C. Kunick, E. Verdin, P. Goekjian, W. Sippl and M. Jung, *J. Med. Chem.*, 2006, **49**, 7307–7316.
- 30 M. Gertz, G. T. T. Nguyen, F. Fischer, B. Suenkel, C. Schlicker, B. Fränzel, J. Tomaschewski, F. Aladini, C. Becker, D. Wolters and C. Steegborn, *PLoS One*, 2012, **7**, 1–12.
- 31 M. T. Borra, B. C. Smith and J. M. Denu, *J. Biol. Chem.*, 2005, **280**, 17187–17195.
- 32 J. J. Johnson, M. Nihal, I. A. Siddiqui, C. O. Scarlett, H. H. Bailey, H. Mukhtar and N. Ahmad, *Mol. Nutr. Food Res.*, 2011, **55**, 1169–1176.
- 33 B. Schmidt, C. Ferreira, C. L. A. Passos, J. L. Silva and E. Fialho, *Int. J. Mol. Sci.*, 2020, **21**(15), 5244.
- 34 A. H. Tantawy, K. A. Soliman and H. M. Abd El-Lateef, *J. Cleaner Prod.*, 2019, 119510.
- 35 A. H. Tantawy, S. M. Farag, L. Hegazy, H. Jiang and M. Q. Wang, *Bioorg. Chem.*, 2019, 103464.
- 36 H. Qu, X. Yu, X. Zhi, M. Lv and H. Xu, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 5552–5557.
- 37 R. Le Goff, M. Sanselme, M. Lawson, A. Daïch and S. Comesse, *Eur. J. Org. Chem.*, 2015, 7244–7248.
- 38 R. Le Goff, A. Martel, M. Sanselme, M. Lawson and A. Dai, *Chem.–Eur. J.*, 2015, **21**, 2966–2979.
- 39 T. Yang, X. Chen, H. X. Jin, G. Sethi and M. L. Go, *Eur. J. Med. Chem.*, 2015, **92**, 145–155.
- 40 M. A. Spackman and J. J. McKinnon, *CrystEngComm*, 2002, **4**, 378–392.
- 41 M. A. Spackman and D. Jayatilaka, *CrystEngComm*, 2009, **11**, 19–32.
- 42 J. J. McKinnon, M. A. Spackman and A. S. Mitchell, *Novel tools for visualizing and exploring intermolecular interactions in molecular crystals*, 2004, vol. 60.
- 43 B. G. M. Youssif, M. H. Abdelrahman, A. H. Abdelazeem, M. A. Abdelgawad, H. M. Ibrahim, O. I. A. Salem and M. F. A. Mohamed, *Eur. J. Med. Chem.*, 2018, **146**, 260–273.
- 44 A. H. Abdelazeem, A. G. Safi El-Din, M. M. Abdel-Fattah, N. H. Amin, S. M. El-Moghazy and M. T. El-Saadi, *Eur. J. Med. Chem.*, 2020, **205**, 112662.
- 45 M. H. Abdelrahman, B. G. M. Youssif, M. A. Abdelgawad, A. H. Abdelazeem, H. M. Ibrahim, A. E. G. A. Moustafa, L. Treamblu and S. N. A. Bukhari, *Eur. J. Med. Chem.*, 2017, **127**, 972–985.
- 46 G. F. Zha, H. L. Qin, B. G. M. Youssif, M. W. Amjad, M. A. G. Raja, A. H. Abdelazeem and S. N. A. Bukhari, *Eur. J. Med. Chem.*, 2017, **135**, 34–48.
- 47 T. Rumpf, M. Schiedel, B. Karaman, C. Roessler, B. J. North, A. Lehotzky, J. Oláh, K. I. Ladwein, K. Schmidtkunz, M. Gajer, M. Pannek, C. Steegborn, D. A. Sinclair, S. Gerhardt, J. Ovádi, M. Schutkowski, W. Sippl, O. Einsle and M. Jung, *Nat. Commun.*, 2015, **6**, 6263.
- 48 S. Swyter, M. Schiedel, D. Monaldi, S. Szunyogh, A. Lehotzky, T. Rumpf, J. Ovádi, W. Sippl and M. Jung, *Philos. Trans. R. Soc., B*, 2018, **373**, 20170083.
- 49 H. Zeng, Z. Luo, X. Han and C. J. Li, *Org. Lett.*, 2019, **21**, 5948–5951.
- 50 D. Zhu, L. Lv, C. Li, S. Ung, J. Gao and C. Li, *Angew. Chem., Int. Ed.*, 2018, **57**, 16520–16524.
- 51 J. Poh, D. N. Tran, C. Battilocchio, J. M. Hawkins and S. V. Ley, *Angew. Chem., Int. Ed.*, 2015, **54**, 7920–7923.
- 52 H. A. M. El-Sherief, B. G. M. Youssif, S. N. A. Bukhari, M. Abdel-Aziz and H. M. Abdel-Rahman, *Bioorg. Chem.*, 2018, **76**, 314–325.
- 53 D. Rotili, D. Tarantino, V. Carafa, E. Lara, S. Meade, G. Botta, A. Nebbioso, M. Jung, A. G. Kazantsev, M. Esteller, M. F. Fraga, L. Altucci and A. Mai, *ChemMedChem*, 2010, 674–677.
- 54 B. G. M. Youssif, A. M. Mohamed, E. Eldin, A. Osman, O. F. Abou-ghadir, D. H. Elnaggar, M. H. Abdelrahman, L. Treamblu and H. A. M. Gomaa, *Eur. J. Med. Chem.*, 2019, **177**, 1–11.
- 55 H. A. Abou-zied, B. G. M. Youssif, M. F. A. Mohamed and A. M. Hayallah, *Bioorg. Chem.*, 2019, **89**, 102997.

